157 related articles for article (PubMed ID: 31454632)
1. Correlation between immunohistochemistry and RICTOR fluorescence in situ hybridization amplification in small cell lung carcinoma.
Krencz I; Sebestyen A; Papay J; Lou Y; Lutz GF; Majewicz TL; Khoor A
Hum Pathol; 2019 Nov; 93():74-80. PubMed ID: 31454632
[TBL] [Abstract][Full Text] [Related]
2.
Krencz I; Sztankovics D; Sebestyén A; Pápay J; Dankó T; Moldvai D; Lutz E; Khoor A
Pathol Oncol Res; 2024; 30():1611593. PubMed ID: 38706776
[No Abstract] [Full Text] [Related]
3. Rapamycin-insensitive companion of mTOR (RICTOR) amplification defines a subset of advanced gastric cancer and is sensitive to AZD2014-mediated mTORC1/2 inhibition.
Kim ST; Kim SY; Klempner SJ; Yoon J; Kim N; Ahn S; Bang H; Kim KM; Park W; Park SH; Park JO; Park YS; Lim HY; Lee SH; Park K; Kang WK; Lee J
Ann Oncol; 2017 Mar; 28(3):547-554. PubMed ID: 28028034
[TBL] [Abstract][Full Text] [Related]
4. Correlation between RICTOR overexpression and amplification in advanced solid tumors.
Bang H; Ahn S; Ji Kim E; Kim ST; Park HY; Lee J; Kim KM
Pathol Res Pract; 2020 Jan; 216(1):152734. PubMed ID: 31740232
[TBL] [Abstract][Full Text] [Related]
5. RICTOR amplification identifies a subgroup in small cell lung cancer and predicts response to drugs targeting mTOR.
Sakre N; Wildey G; Behtaj M; Kresak A; Yang M; Fu P; Dowlati A
Oncotarget; 2017 Jan; 8(4):5992-6002. PubMed ID: 27863413
[TBL] [Abstract][Full Text] [Related]
6. Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer.
Zhang L; Yu H; Badzio A; Boyle TA; Schildhaus HU; Lu X; Dziadziuszko R; Jassem J; Varella-Garcia M; Heasley LE; Kowalewski AA; Ellison K; Chen G; Zhou C; Hirsch FR
J Thorac Oncol; 2015 Jul; 10(7):1083-90. PubMed ID: 26020126
[TBL] [Abstract][Full Text] [Related]
7.
Kim LC; Rhee CH; Chen J
Mol Cancer Res; 2020 Nov; 18(11):1675-1684. PubMed ID: 32801163
[TBL] [Abstract][Full Text] [Related]
8. Myc protein expression correlates with MYC amplification in small-cell lung carcinoma.
Hwang DH; Sun H; Rodig SJ; Hornick JL; Sholl LM
Histopathology; 2015 Jul; 67(1):81-9. PubMed ID: 25407018
[TBL] [Abstract][Full Text] [Related]
9. Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis.
Morrison Joly M; Williams MM; Hicks DJ; Jones B; Sanchez V; Young CD; Sarbassov DD; Muller WJ; Brantley-Sieders D; Cook RS
Breast Cancer Res; 2017 Jun; 19(1):74. PubMed ID: 28666462
[TBL] [Abstract][Full Text] [Related]
10. Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex.
Gkountakos A; Pilotto S; Mafficini A; Vicentini C; Simbolo M; Milella M; Tortora G; Scarpa A; Bria E; Corbo V
Carcinogenesis; 2018 Jul; 39(8):971-980. PubMed ID: 29955840
[TBL] [Abstract][Full Text] [Related]
11. mTOR hyperactivity and
Sztankovics D; Moldvai D; Petővári G; Dankó T; Szalai F; Miyaura R; Varga V; Nagy N; Papp G; Pápay J; Krencz I; Sebestyén A
Pathol Oncol Res; 2024; 30():1611643. PubMed ID: 38515456
[TBL] [Abstract][Full Text] [Related]
12. RICTOR Amplification Defines a Novel Subset of Patients with Lung Cancer Who May Benefit from Treatment with mTORC1/2 Inhibitors.
Cheng H; Zou Y; Ross JS; Wang K; Liu X; Halmos B; Ali SM; Liu H; Verma A; Montagna C; Chachoua A; Goel S; Schwartz EL; Zhu C; Shan J; Yu Y; Gritsman K; Yelensky R; Lipson D; Otto G; Hawryluk M; Stephens PJ; Miller VA; Piperdi B; Perez-Soler R
Cancer Discov; 2015 Dec; 5(12):1262-70. PubMed ID: 26370156
[TBL] [Abstract][Full Text] [Related]
13. Correlation of IHC and FISH for ALK gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH.
Yi ES; Boland JM; Maleszewski JJ; Roden AC; Oliveira AM; Aubry MC; Erickson-Johnson MR; Caron BL; Li Y; Tang H; Stoddard S; Wampfler J; Kulig K; Yang P
J Thorac Oncol; 2011 Mar; 6(3):459-65. PubMed ID: 21278610
[TBL] [Abstract][Full Text] [Related]
14. Fibroblast growth factor receptor 1 gene amplification and protein expression in human lung cancer.
Elakad O; Lois AM; Schmitz K; Yao S; Hugo S; Lukat L; Hinterthaner M; Danner BC; von Hammerstein-Equord A; Reuter-Jessen K; Schildhaus HU; Ströbel P; Bohnenberger H
Cancer Med; 2020 May; 9(10):3574-3583. PubMed ID: 32207251
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of mTORC2/RICTOR Impairs Melanoma Hepatic Metastasis.
Schmidt KM; Dietrich P; Hackl C; Guenzle J; Bronsert P; Wagner C; Fichtner-Feigl S; Schlitt HJ; Geissler EK; Hellerbrand C; Lang SA
Neoplasia; 2018 Dec; 20(12):1198-1208. PubMed ID: 30404068
[TBL] [Abstract][Full Text] [Related]
16. Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma.
Krencz I; Sebestyén A; Fábián K; Márk Á; Moldvay J; Khoor A; Kopper L; Pápay J
Hum Pathol; 2017 Apr; 62():66-73. PubMed ID: 28025080
[TBL] [Abstract][Full Text] [Related]
17. MYCL1 Amplification and Expression of L-Myc and c-Myc in Surgically Resected Small-Cell Lung Carcinoma.
Qin J; Xie F; Li C; Han N; Lu H
Pathol Oncol Res; 2021; 27():1609775. PubMed ID: 34257619
[No Abstract] [Full Text] [Related]
18. Down-regulation of Rictor enhances cell sensitivity to PI3K inhibitor LY294002 by blocking mTORC2-medicated phosphorylation of Akt/PRAS40 in esophageal squamous cell carcinoma.
Hou G; Zhao Q; Zhang M; Fan T; Liu M; Shi X; Ren Y; Wang Y; Zhou J; Lu Z
Biomed Pharmacother; 2018 Oct; 106():1348-1356. PubMed ID: 30119206
[TBL] [Abstract][Full Text] [Related]
19. Detection of ALK rearrangements in malignant pleural effusion cell blocks from patients with advanced non-small cell lung cancer: a comparison of Ventana immunohistochemistry and fluorescence in situ hybridization.
Wang W; Tang Y; Li J; Jiang L; Jiang Y; Su X
Cancer Cytopathol; 2015 Feb; 123(2):117-22. PubMed ID: 25529354
[TBL] [Abstract][Full Text] [Related]
20. Synergistic Effects between mTOR Complex 1/2 and Glycolysis Inhibitors in Non-Small-Cell Lung Carcinoma Cells.
Jiang S; Zou Z; Nie P; Wen R; Xiao Y; Tang J
PLoS One; 2015; 10(7):e0132880. PubMed ID: 26176608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
